about
P1346
WNT16 influences bone mineral density, cortical bone thickness, bone strength, and osteoporotic fracture riskCalcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysisCalcium intake and bone mineral density: systematic review and meta-analysisCalcium intake and risk of fracture: systematic reviewDiagnosis and management of osteonecrosis of the jaw: a systematic review and international consensusDenosumab for prevention of fractures in postmenopausal women with osteoporosisCase-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ.Genetic determinants of heel bone properties: genome-wide association meta-analysis and replication in the GEFOS/GENOMOS consortiumDeterminants of vitamin D status in older men living in a subtropical climate.Vitamin D insufficiency and health outcomes over 5 y in older women.Genome-wide association study using extreme truncate selection identifies novel genes affecting bone mineral density and fracture riskA single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years.Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.Calcium supplements and cardiovascular risk: 5 years onGenome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture.Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis.The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis.Vitamin D supplementation and falls: a trial sequential meta-analysis.Paget's disease of bone: an endocrine society clinical practice guideline.Cardiovascular complications of calcium supplements.Calcium supplements: benefits and risks.Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial.Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial.Pathogenesis and management of Paget's disease of bone.Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivoConcordance of Results from Randomized and Observational Analyses within the Same Study: A Re-Analysis of the Women's Health Initiative Limited-Access Dataset.Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures.The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).Differences between self-reported and verified adverse cardiovascular events in a randomised clinical trialTime to onset of antifracture efficacy and year-by-year persistence of effect of zoledronic acid in women with osteoporosisRelationships between fat and bone.Cardiovascular effects of calcium supplementsCalcium supplementation and vascular disease.Randomised controlled trial of vitamin D supplementation in sarcoidosis.Anti-resorptive therapies for osteoporosis.Osteonecrosis of the jaw: who gets it, and why?Once-yearly zoledronic acid and days of disability, bed rest, and back pain: randomized, controlled HORIZON Pivotal Fracture Trial.Multistage genome-wide association meta-analyses identified two new loci for bone mineral densityDoes calcium supplementation increase cardiovascular risk?Fat and bone.
P50
Q21090209-D1F06BE4-A7B6-476C-BAE2-F27765503444Q24548778-351793CD-224F-4D22-B758-60EF2193EC4CQ26784337-FCB3672F-76BE-4227-9D63-61586854B63FQ26784357-C5F84FB3-C1A8-4646-9089-1991C124200FQ26996169-D7669564-3D0B-46CC-86A0-8946CA089785Q28254528-F01F8A27-B6B8-415B-AF27-40F64031CC76Q30240109-A923D07A-53AD-406F-9C24-B14798FAEB82Q30579240-E504535E-AE8A-4D78-A46C-525DFB4DBF90Q33845051-147BF61F-0F53-4F40-88F7-0E61732F898EQ33846036-71C7F6CD-BED0-45D1-A051-11E7BAF3B12CQ33885943-F4255E8F-E264-46C1-B3C4-90AA52990720Q33921570-F90F1E9B-92E3-41B4-B9E8-877C4E84B67EQ34003925-22C62FF3-E8BB-4ADF-982B-16A9FBE5E24DQ34016231-840EC18E-3198-4D70-A609-AEB90D311BF5Q34268288-1F30F6B6-4AD6-43C1-8261-F949A19C33D3Q34377336-080256CE-CB7B-4F7C-9DAE-764EED2049E1Q34413712-B362EE86-F84D-4FE4-AC52-47BF6605467DQ34417236-B9C201EE-2888-4B08-B417-7A4D6866C242Q34448424-A2BD89CC-B69D-4ED6-904D-899C10F330A5Q34452938-C09E4C49-E89D-4F23-BD69-320BA6E98CD0Q34485049-13A99404-2760-4ACA-B560-C5EA7839D856Q34587149-67D67CEC-6EAC-4287-A740-354B745BD1E1Q34732203-382DF87E-C235-4C2A-8EC9-CA28C4BFDC5BQ34795095-4BF03FA4-4129-42A6-917D-B822F59AF702Q35748476-B44EF75B-C8F4-494B-BCF0-95337118F354Q36126565-3A8A6A1E-E1D3-41F3-8E76-89C73476ABF0Q36153174-ED3E3C43-5AD9-4FF0-B6D6-5634251E3E30Q36190027-E2C31F68-4CE4-46A3-909C-207F87DA83A2Q36730009-791CABAC-13FA-4AB5-885B-ACEB04A6191EQ36795687-92BBF14B-A957-422F-B0F4-2108A4BB7647Q36983729-3D2A2387-0580-4DE8-92E6-481B0EBD959CQ37083789-6A2C13A6-E958-4D5D-8132-60B7C57112CAQ37223483-24706C71-9D7C-4094-A7B4-5C7F664066D0Q37256476-E1216868-C5F1-4DEE-B190-F26252F5FDE4Q37257184-BD4568EE-0697-4F61-BE15-A90432DBE42EQ37307232-EFEC2B88-E068-48F9-8667-2F89BF4B5423Q37407743-EE165B69-0ADF-4A09-81F2-D57E27D4AAD4Q37619295-3A4268D1-B722-45A7-A1AF-044E8DCFDE81Q37698674-9ED25DA4-4A0A-4B1E-8087-BE4CF91C23D7Q37769794-2E922164-585B-4AFF-B234-0B7D367C31C5
P50
description
New Zealand endocrinologist, professor and researcher
@en
endocrinoloog uit Nieuw-Zeeland
@nl
name
Ian Reid
@ast
Ian Reid
@en
Ian Reid
@es
Ian Reid
@fr
Ian Reid
@nl
Ian Reid
@sl
Ian Reid
@sq
type
label
Ian Reid
@ast
Ian Reid
@en
Ian Reid
@es
Ian Reid
@fr
Ian Reid
@nl
Ian Reid
@sl
Ian Reid
@sq
altLabel
I. R. Reid
@en
Ian Reginald Reid
@en
prefLabel
Ian Reid
@ast
Ian Reid
@en
Ian Reid
@es
Ian Reid
@fr
Ian Reid
@nl
Ian Reid
@sl
Ian Reid
@sq
P166
P21
P27
P31
P496
0000-0001-6021-5458